# US 2010/0167322 A1 · Method of detecting cerebral stroke or asymptomatic cerebral infarction using acrolein, interleukin-6 and crp contents, polyamine oxidase activity or polyamine oxidase protein content and subject's age as indicators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167322 A1
- Document ID: US20100167322A1
- Status: Published application
- Kind: A1
- Application number: 12/598,125
- Filed: 2008-02-19
- Published: 2010-07-01
- Earliest claimed: 2007-05-18
- Assignees: National University Corporation Chiba University
- Inventors: Kazuei Igarashi; Shinjyuro Namiki; Madoka Yoshida
- Web page: https://patentgrep.com/patent/US20100167322A1

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 2333/4737: C-reactive protein
- G01N 2333/5412: IL-6
- G01N 2333/902: Oxidoreductases (1.)
- G01N 2800/2871: Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
- Y10T 436/200833: Carbonyl, ether, aldehyde or ketone containing
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

A method of detecting cerebral stroke or asymptomatic cerebral infarction is disclosed. The method comprises measuring the contents of aldehyde compounds formed from polyamines, interleukin-6 and C-reactive proteins, the polyamine oxidase activity or the polyamine oxidase protein content in a biological sample obtained from a subject and using the measurement data thus obtained and the age of the subject as indications. Also disclosed is a kit for conducting this detection method; and a system for detecting cerebral stroke or asymptomatic cerebral infarction which comprises this kit.

## Claims

### Claim 1

A method of detecting asymptomatic cerebral infarction, comprising:
measuring, in a biological sample obtained from a subject, one or more of the biomarkers selected from the group consisting of:
(a) content of an aldehyde compound formed from polyamine,
(b) content of interleukin-6,
(c) content of C-reactive protein, and polyamine oxidase activity or content of polyamine oxidase protein; and
determining a likelihood of asymptomatic cerebral infarction in the subject based on the result of the measuring step and the age of the subject.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the aldehyde compound formed from the polyamine is acrolein.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the determining step.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the statistical analysis is performed by a neural network technique.

### Claim 5

A kit for detecting asymptomatic cerebral infarction in a subject, comprising;
a reagent for measuring, in a biological sample obtained from the subject,
(a) content of an aldehyde compound fowled from polyamine,
(b) content of interleukin-6,
(c) content of C-reactive protein, and
(d) polyamine oxidase activity or content of polyamine oxidase protein; and
an instruction on how to determining a likelihood of asymptomatic cerebral infarction in the subject based on the measured value of one or more of (a)-(e) and the age of the subject.

### Claim 6

A system for detecting asymptomatic cerebral infarction in a subject, comprising:
a reagent for measuring, in a biological sample obtained from the subject,
(a) content of an aldehyde compound formed from polyamine,
(b) content of interleukin-6,
(c) content of C-reactive protein, or
(d) polyamine oxidase activity or content of polyamine oxidase protein;
a computer; and
software for carrying out statistical analysis.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the likelihood of asymptomatic cerebral infarction is determined with an accuracy of 95% or more.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the likelihood of asymptomatic cerebral infarction is determined with sensitivity of 95.5% or more and a specificity of 94.3% or more.

### Claim 9 (depends on 1)

The method of claim 1, wherein the measuring step measures (a) and one of (b)-(d).

### Claim 10 (depends on 1)

The method of claim 1, wherein the measuring step measures (a), (b) and one of (c)-(d).

### Claim 11 (depends on 1)

The method of claim 1, wherein the measuring step measures (a)-(d).

### Claim 12 (depends on 1)

The method of claim 1, wherein the biological sample is plasma sample.

### Claim 13 (depends on 1)

The method of claim 1, wherein the measuring step is performed using ELISA.

### Claim 14 (depends on 5)

The kit of claim 5, comprising reagents for measuring, in a biological sample obtained from the subject,
(a) content of an aldehyde compound formed from polyamine,
(b) content of interleukin-6,
(c) content of C-reactive protein, and
(d) polyamine oxidase activity or content of polyamine oxidase protein.